✦ LIBER ✦

Collaborative experience of open-label infliximab in refractory pediatric Crohn's disease

✍ Scribed by Eric A. Vasiliauskas; Sharon Schaffer; Carl V. Dezenberg; Howard I. Baron; James M. Noel; Prathiba Nanjundiah; Vikram Khosoo; William F. Marshall; Daniel W. Thomas

Book ID: 119425907
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 167 KB
Volume: 118
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(00)82787-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of infliximab in pediatric Croh

Efficacy of infliximab in pediatric Crohn's disease: A randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy

✍ Frank M. Ruemmele; Alain Lachaux; Jean-Pierre Cézard; Alain Morali; Chantal Maur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

## Background: Infliximab (ifx) is efficacious in inducing remission in severe forms of pediatric crohn's disease (cd). adult studies indicate that ifx is also safe and well tolerated as maintenance therapy. the present study aimed to evaluate in a prospective manner the efficacy and safety of ifx

Response to infliximab in “acute” and in

Response to infliximab in “acute” and in refractory colonic Crohn’s disease: a preliminary experience

✍ Arrigo Arrigoni; Tatiana Sprujevnik; Alberto Bertone; Mauro Spandre; Renato Sant 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 25 KB

Response to infliximab in “acute” and in

Response to infliximab in “acute” and in refractory colonic crohn's disease: A preliminary experience

✍ Arrigo Arrigoni; Tatiana Sprujevnik; Alberio Bertone; Mauro Spandre; Renato Sant 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 147 KB

Improvement of arthritis and arthralgia

Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn’s disease

✍ Hans Herfarth; Florian Obermeier; Tilo Andus; Gerhard Rogler; Susanna Nikolaus; 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 66 KB

Infliximab (REMICADE) therapy in the tre

Infliximab (REMICADE) therapy in the treatment of pediatric Crohn’s disease

✍ Robert Baldassano; Christian P Braegger; Johanna C Escher; Kimberly DeWoody; Dav 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 153 KB

Durability of infliximab in Crohn's dise

Durability of infliximab in Crohn's disease: A single-center experience

✍ Jason E. Gonzaga; Ashwin N. Ananthakrishnan; Mazen Issa; Dawn B. Beaulieu; Sue S 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 2 views

Background: Infliximab is effective maintenance for moderate to severe Crohn's disease (CD); however, problems with immunogenicity and decreased efficacy often complicate long-term use. Durability of infliximab maintenance therapy over multiple years has not been defined. ## Methods: This was a r